Recently, three studies which were conducted in the United States (27), Russia (28), and China (29) used gene panel sequencing to screen the multi-gene germline mutations in high-risk BRCA1/2-negative breast cancer patients, yet none of the FANCC germline mutations were found. This evidence concerns the gene FANCC and breast cancer.